Curculigoside Protects against Titanium Particle-Induced Osteolysis through the Enhancement of Osteoblast Differentiation and Reduction of Osteoclast Formation

Abstract

Wear particle-induced periprosthetic osteolysis is mainly responsible for joint replacement failure and revision surgery. Curculigoside is reported to have bone-protective potential, but whether curculigoside attenuates wear particle-induced osteolysis remains unclear. In this study, titanium particles (Ti) were used to stimulate osteoblastic MC3T3-E1 cells in the presence or absence of curculigoside, to determine their effect on osteoblast differentiation. Rat osteoclastic bone marrow stromal cells (BMSCs) were cocultured with Ti in the presence or absence of curculigoside, to evaluate its effect on osteoclast formation in vitro. Ti was also used to stimulate mouse calvaria to induce an osteolysis model, and curculigoside was administrated to evaluate its effect in the osteolysis model by micro-CT imaging and histopathological analyses. As the results indicated, in MC3T3-E1 cells, curculigoside treatment attenuated the Ti-induced inhibition on cell differentiation and apoptosis, increased alkaline phosphatase activity (ALP) and cell mineralization, and inhibited TNF-α, IL-1β, and IL-6 production and ROS generation. In BMSCs, curculigoside treatment suppressed the Ti-induced cell formation and suppressed the TNF-α, IL-1β, and IL-6 production and F-actin ring formation. In vivo, curculigoside attenuated Ti-induced bone loss and histological damage in murine calvaria. Curculigoside treatment also reversed the RANK/RANKL/OPG and NF-κB signaling pathways, by suppressing the RANKL and NF-κB expression, while activating the OPG expression. Our study demonstrated that curculigoside treatment was able to attenuate wear particle-induced periprosthetic osteolysis in in vivo and in vitro experiments, promoted osteoblastic MC3T3-E1 cell differentiation, and inhibited osteoclast BMSC formation. It suggests that curculigoside may be a potential pharmaceutical agent for wear particle-stimulated osteolysis therapy.

Phosphatidyl Inositol 3-Kinase (PI3K)-Inhibitor CDZ173 protects against LPS-induced osteolysis

“…Thus, the mutually beneficial interaction of these 2 cells ensures that the structural integrity of skeletal tissue is kept in the best possible condition (Mediero and Cronstein, 2013). However, when osteoclasts are overactivated and gradually become dominant, bone resorption is more substantial than bone formation, leading to osteolytic diseases, including rheumatoid arthritis, periodontitis, aseptic sterility after joint replacement, and bone loss induced by prosthesis loosening (Zhu et al, 2021;Gao et al, 2022). Notably, joint replacement is still the most direct and effective surgery for patients with advanced bone disease.…”

The effect of QiangGuYin on osteoporosis through the AKT/mTOR/autophagy signaling pathway mediated by CKIP-1

“…RANKL (receptor activator of nuclear factor kappa B ligand) is a key osteoclast differentiation factor, which is secreted in large quantities by fibroblasts, osteoblasts and stromal cells around the prosthesis. It combines RANK and cooperates with NF-κB, promote osteoclast differentiation and survival, and osteoclast bone resorption; OPG, as an osteoclast differentiation inhibitor, usually competes with RANK to integrate RANKL, blocking the promotion effect of RANKL/RANK on osteoclast and osteoclast bone resorption, thereby inhibiting osteolysis [42]. The imbalance between osteoblast bone formation and osteoclast bone resorption ultimately leads to osteolysis around the prosthesis, where the OPG/RANKL ratio is one of the best characterizing biomarkers related to the pathology of bone destruction [43].…”

Human umbilical cord mesenchymal stromal cells promotes the proliferation and osteogenic differentiation of autologous bone marrow stem cells by secreting exosomes

“…The process of fracture healing requires the production of a large number of new osteoblasts, which accelerates bone synthesis and calcification, and increases bone volume and density [ 27 ]. As the body ages, the number of ABMSCs functional cells decreases, and their potential to differentiate into osteoblasts in the bone marrow is down-regulated [ 28 , 29 ]. Meanwhile, senescence-related secretory phenotypic molecules act in the bone microenvironment and inhibit the osteogenic differentiation of ABMSCs.…”